search
Back to results

Snacks and Satiety

Primary Purpose

Eating Behavior, Overweight, Obesity

Status
Terminated
Phase
Not Applicable
Locations
United States
Study Type
Interventional
Intervention
Almond snack
Cereal-based snack
Sponsored by
USDA, Western Human Nutrition Research Center
About
Eligibility
Locations
Arms
Outcomes
Full info

About this trial

This is an interventional basic science trial for Eating Behavior focused on measuring satiety, gastrointestinal hormones, appetite, Dietary fiber, food cravings

Eligibility Criteria

18 Years - 45 Years (Adult)FemaleAccepts Healthy Volunteers

Inclusion Criteria:

  • Pre-menopausal
  • Body Mass Index 25 - 39.9 kg/m2

Exclusion Criteria:

  • Women who are post-menopausal or peri-menopausal
  • BMI < 25 or > 40 kg/m2
  • Allergies to tree nuts
  • Using any hormonal contraception including oral contraceptive, contraceptive patch, contraceptive ring, contraceptive injection (e.g. Depo-Provera), or contraceptive implant (e.g. Nexplanon/Implanon)
  • Menstrual cycle lengths < 25 days or > 45 days, or have amenorrhea, eumenorrhea, or polymenorrhea.
  • Pregnant or nursing within the last 6 months, or plan to become pregnant during the trial
  • Medical diagnoses of chronic diseases including cardiovascular or pulmonary diseases, renal disease, cancer, type 1 or type 2 diabetes mellitus, thyroid disease requiring medication, inflammatory bowel disease, irritable bowel disease, or those with recent major surgeries
  • current medical diagnosis of polycystic ovarian syndrome (PCOS).

Sites / Locations

  • USDA, ARS, Western Human Nutrition Research Center

Arms of the Study

Arm 1

Arm 2

Arm Type

Experimental

Experimental

Arm Label

Almond snack

Cereal-based snack

Arm Description

The almond intervention will be roasted almonds 56 grams/day for 28 days. The caloric value is approximately 350 kcals.

The cereal-based intervention will be a mixture of dry cereal, pretzels, and bread sticks prepared by the Western Human Nutrition Research Center (WHNRC). The caloric value is approximately 350 kcals.

Outcomes

Primary Outcome Measures

Baseline level and change in cholecystokinin
Cholecystokinin (CCK) measured in blood using an antibody based assay
Baseline level and change in peptide-YY
Peptide-YY (PYY) measured in blood using an antibody based assay
Baseline level and change in glucose-like peptide 1
Glucose-like peptide 1 (GLP-1) measured in blood using an antibody based assay
Baseline level and change in gastric inhibitory peptide
Gastric inhibitory peptide (GIP) measured in blood using an antibody based assay
Baseline level and change in insulin
Insulin measured in blood using an antibody based assay
Baseline level and change in glucose
Glucose measured by standard chemistry in blood
Baseline level and change in oleoylethanolamide
Oleoylethanolamide measured by mass spectrometry in blood
Baseline level and change in ghrelin
Ghrelin measured in blood using an antibody based assay
Baseline level and change in leptin
Leptin measured in blood using an antibody based assay
Baseline level and change in orexin
Orexin measured in blood using an antibody based assay
Baseline level and change in endocannabinoid profiles
Endocannabinoid profiles measured by mass spectrometry in blood
Baseline level and change in hunger
Self-reported feelings of hunger measured on a visual analog scale. Responses will be a marked on an unsegmented line from 0 or "not at all" to 100 or "extremely."
Baseline level and change in satiety
Self-reported feelings of fullness measured on a visual analog scale. Responses will be a marked on an unsegmented line from 0 or "not at all" to 100 or "extremely."
Change in food intake at a dinner meal
Calories consumed at a dinner meal following the satiety protocol

Secondary Outcome Measures

Body composition reference measurement
Body composition (fat mass and fat-free mass in kg) will be measured once during the study using dual energy x-ray absorptiometry (DEXA)
Change in body weight
measured in kg
Change in body fat
measured in kg using multi frequency bioimpedance
Change in lean body mass
measured in kg using multi frequency bioimpedance
Change in total body water
measured in kg using multi frequency bioimpedance
Change in waist circumference
measured in cm
Change in hip circumference
measured in cm
Change in Food Choice
Food choice computer-based tests from Leeds, United Kingdom, will be used to estimate explicit liking and implicit wanting for several different categories of foods.
Change in food craving
Food craving estimated from the questionnaire, Food Craving Inventory, on a 5 point likert scale
Change in self-reported satiety
Self reported satiety measured using the 5-factor satiety questionnaire. Scale is a generalized labeled magnitude scale of 150 mm Subscales include mental hunger, physical hunger, mental fullness, physical fullness, and satiation. Subscale scores will range from 0 to 150.
Power of food questionnaire
Power of food questionnaire measured once on a 5 point likert scale
Food addiction questionnaire
Yale food addiction questionnaire measured once on a 5-point likert scale
Eating behavior
Dutch eating behavior questionnaire measured once. Scale is a 5-point likert scale. Sub scales include restrained eating, emotional eating, and external eating. Scores will be reported separately for each subscale.
Three factor eating inventory
Three factor eating inventory questionnaire measured once. Instrument has three subscales, combining likert scales and true/false questions. Subscales include cognitive restraint (score can range from 0 to 21), disinhibition (score can range from 0 to 16) and hunger (score can range from 0 to 14).
Premenstrual Syndrome
Premenstrual Syndrome screening questionnaire measured once. Scale is a 4-point likert. Subscales for premenstrual syndrome (PMS) or premenstrual dysphoric disorder (PMDD), reported separately.
General health and well-being
The SF-36 General Health and Well-being questionnaire measured once
Usual physical activity
Physical activity estimated from the Stanford Brief Physical Activity questionnaire. Scale is categorical for two subscales: work physical activity and leisure time activity.
Change in metabolic rate
Resting and post-prandial metabolic rate measured using indirect calorimetry.
Change in dietary intake
Dietary intake estimated from 24-hour recall using a web based automated multi-pass method
Genetic risk of obesity
A polygenic risk score (PRS) indexing genetic predisposition to obesity using known obesity single nucleotide polymorphisms (SNPs).
Change in liver fat
Liver fat assessed from the Controlled Attenuation Parameter (CAP) computed from the liver stiffness measurement using the Fibroscan®
Change in liver stiffness
Liver stiffness assessed from the shear wave speed with pulse echo ultrasound using the Fibroscan®

Full Information

First Posted
May 9, 2019
Last Updated
August 8, 2022
Sponsor
USDA, Western Human Nutrition Research Center
Collaborators
Almond Board of California
search

1. Study Identification

Unique Protocol Identification Number
NCT03947281
Brief Title
Snacks and Satiety
Official Title
Almond Snacks and Satiety: A Randomized Intervention Trial Examining Acute and Chronic Effects
Study Type
Interventional

2. Study Status

Record Verification Date
August 2022
Overall Recruitment Status
Terminated
Why Stopped
After delay due to pandemic, sponsor declined to continue funding.
Study Start Date
June 24, 2019 (Actual)
Primary Completion Date
August 8, 2022 (Actual)
Study Completion Date
August 8, 2022 (Actual)

3. Sponsor/Collaborators

Responsible Party, by Official Title
Sponsor
Name of the Sponsor
USDA, Western Human Nutrition Research Center
Collaborators
Almond Board of California

4. Oversight

Studies a U.S. FDA-regulated Drug Product
No
Studies a U.S. FDA-regulated Device Product
No
Data Monitoring Committee
No

5. Study Description

Brief Summary
This study is designed to compare two types of snacks (almonds or a cereal-based snack), eaten between meals, on measures of appetite, including appetitive hormones, self-reported feelings of hunger and fullness, and food intake at a buffet meal or in the home environment. The investigators hypothesize that the acute responses of appetitive hormones to a meal challenge protocol will differ between almond and cereal-based snacks based on multivariate models of satiety that will be predictive of ad libitum food intake at a dinner meal as part of the meal challenge protocol. Further, the investigators will estimate if, under free-living conditions, self-selected and self-reported food intake will show appropriate energy compensation for the added calories of the snacks, and determine if one type of snack is superior to the other in this regard.
Detailed Description
This study will use a randomized, parallel design that includes an almond snack intervention and a cereal-based snack intervention group. The almond intervention will be roasted, unsalted almonds at a level of 56 grams per day for 4 weeks. The cereal-based intervention will be isocaloric snacks provided in the form of a mixture of dry cereal, pretzels, and bread sticks for 4 weeks. A satiety test protocol will be done at the beginning and the end of the intervention period. Each test day will include measures of satiety responses to two standard meals, two snacks (either almonds or cereal-based snacks), and a dinner buffet. The protocol to evaluate satiety signals include tonic measures that may signal homeostasis to the brain and evaluation of episodic signals that may drive food intake In addition, other modulators of satiety will be tested including evaluation of preferences for palatable foods, self-reports of cravings and satiety using questionnaires, and perceived hunger, fullness, desire to eat.

6. Conditions and Keywords

Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
Eating Behavior, Overweight, Obesity
Keywords
satiety, gastrointestinal hormones, appetite, Dietary fiber, food cravings

7. Study Design

Primary Purpose
Basic Science
Study Phase
Not Applicable
Interventional Study Model
Parallel Assignment
Model Description
The study will be a randomized, parallel design that includes an almond snack group and a cereal-based snack group. The intervention will be for 28 days. The almond intervention will be roasted almonds 56 grams/day. The cereal-based snack intervention will be the caloric equivalent.
Masking
Outcomes Assessor
Masking Description
Both the investigator and the participant will be aware of the group assignment. The persons handling the data and statistics will not be aware of the group assignment.
Allocation
Randomized
Enrollment
10 (Actual)

8. Arms, Groups, and Interventions

Arm Title
Almond snack
Arm Type
Experimental
Arm Description
The almond intervention will be roasted almonds 56 grams/day for 28 days. The caloric value is approximately 350 kcals.
Arm Title
Cereal-based snack
Arm Type
Experimental
Arm Description
The cereal-based intervention will be a mixture of dry cereal, pretzels, and bread sticks prepared by the Western Human Nutrition Research Center (WHNRC). The caloric value is approximately 350 kcals.
Intervention Type
Other
Intervention Name(s)
Almond snack
Intervention Description
The almond intervention will be roasted, unsalted almonds provided at 56 g/day for 28 days. Almonds provide approximately 350 kcals/day.
Intervention Type
Other
Intervention Name(s)
Cereal-based snack
Intervention Description
The cereal-based intervention will be a prepared mix of cereal, pretzels, and bread sticks prepared at the WHNRC. It will be provided at the level of 350 kcals per day for 28 days.
Primary Outcome Measure Information:
Title
Baseline level and change in cholecystokinin
Description
Cholecystokinin (CCK) measured in blood using an antibody based assay
Time Frame
Baseline, 60 minutes before lunch meal, and 10, 30, 90, 150, 180, 210, 240, and 270 minutes after a lunch meal
Title
Baseline level and change in peptide-YY
Description
Peptide-YY (PYY) measured in blood using an antibody based assay
Time Frame
Baseline, 60 minutes before lunch meal, and 10, 30, 90, 150, 180, 210, 240, and 270 minutes after a lunch meal
Title
Baseline level and change in glucose-like peptide 1
Description
Glucose-like peptide 1 (GLP-1) measured in blood using an antibody based assay
Time Frame
Baseline, 60 minutes before lunch meal, and 10, 30, 90, 150, 180, 210, 240, and 270 minutes after a lunch meal
Title
Baseline level and change in gastric inhibitory peptide
Description
Gastric inhibitory peptide (GIP) measured in blood using an antibody based assay
Time Frame
Baseline, 60 minutes before lunch meal, and 10, 30, 90, 150, 180, 210, 240, and 270 minutes after a lunch meal
Title
Baseline level and change in insulin
Description
Insulin measured in blood using an antibody based assay
Time Frame
Baseline, 60 minutes before lunch meal, and 10, 30, 90, 150, 180, 210, 240, and 270 minutes after a lunch meal
Title
Baseline level and change in glucose
Description
Glucose measured by standard chemistry in blood
Time Frame
Baseline, 60 minutes before lunch meal, and 10, 30, 90, 150, 180, 210, 240, and 270 minutes after a lunch meal
Title
Baseline level and change in oleoylethanolamide
Description
Oleoylethanolamide measured by mass spectrometry in blood
Time Frame
Baseline, 60 minutes before lunch meal, and 10, 30, 90, 150, 180, 210, 240, and 270 minutes after a lunch meal
Title
Baseline level and change in ghrelin
Description
Ghrelin measured in blood using an antibody based assay
Time Frame
Baseline, 60 minutes before lunch meal, and 10, 30, 90, 150, 180, 210, 240, and 270 minutes after a lunch meal
Title
Baseline level and change in leptin
Description
Leptin measured in blood using an antibody based assay
Time Frame
Baseline, 60 minutes before lunch meal, and 10, 30, 90, 150, 180, 210, 240, and 270 minutes after a lunch meal
Title
Baseline level and change in orexin
Description
Orexin measured in blood using an antibody based assay
Time Frame
Baseline, 60 minutes before lunch meal, and 10, 30, 90, 150, 180, 210, 240, and 270 minutes after a lunch meal
Title
Baseline level and change in endocannabinoid profiles
Description
Endocannabinoid profiles measured by mass spectrometry in blood
Time Frame
Baseline, 60 minutes before lunch meal, and 10, 30, and 150 minutes after a lunch meal
Title
Baseline level and change in hunger
Description
Self-reported feelings of hunger measured on a visual analog scale. Responses will be a marked on an unsegmented line from 0 or "not at all" to 100 or "extremely."
Time Frame
Baseline, every 30 minutes up to 480 minutes, and immediately before and after three meals
Title
Baseline level and change in satiety
Description
Self-reported feelings of fullness measured on a visual analog scale. Responses will be a marked on an unsegmented line from 0 or "not at all" to 100 or "extremely."
Time Frame
Baseline, every 30 minutes up to 480 minutes, and immediately before and after three meals
Title
Change in food intake at a dinner meal
Description
Calories consumed at a dinner meal following the satiety protocol
Time Frame
Week 1 and 4
Secondary Outcome Measure Information:
Title
Body composition reference measurement
Description
Body composition (fat mass and fat-free mass in kg) will be measured once during the study using dual energy x-ray absorptiometry (DEXA)
Time Frame
Week 1
Title
Change in body weight
Description
measured in kg
Time Frame
Weeks 0, 1, 2, 3, and 4
Title
Change in body fat
Description
measured in kg using multi frequency bioimpedance
Time Frame
Weeks 0, 1, 2, 3, and 4
Title
Change in lean body mass
Description
measured in kg using multi frequency bioimpedance
Time Frame
Weeks 0, 1, 2, 3, and 4
Title
Change in total body water
Description
measured in kg using multi frequency bioimpedance
Time Frame
Weeks 0, 1, 2, 3, and 4
Title
Change in waist circumference
Description
measured in cm
Time Frame
Week 0 and 4
Title
Change in hip circumference
Description
measured in cm
Time Frame
Week 0 and 4
Title
Change in Food Choice
Description
Food choice computer-based tests from Leeds, United Kingdom, will be used to estimate explicit liking and implicit wanting for several different categories of foods.
Time Frame
Baseline and following a lunch meal at Weeks 0 and 4
Title
Change in food craving
Description
Food craving estimated from the questionnaire, Food Craving Inventory, on a 5 point likert scale
Time Frame
Week 0 and 4
Title
Change in self-reported satiety
Description
Self reported satiety measured using the 5-factor satiety questionnaire. Scale is a generalized labeled magnitude scale of 150 mm Subscales include mental hunger, physical hunger, mental fullness, physical fullness, and satiation. Subscale scores will range from 0 to 150.
Time Frame
Week 0 and 4
Title
Power of food questionnaire
Description
Power of food questionnaire measured once on a 5 point likert scale
Time Frame
Week 0
Title
Food addiction questionnaire
Description
Yale food addiction questionnaire measured once on a 5-point likert scale
Time Frame
Week 0
Title
Eating behavior
Description
Dutch eating behavior questionnaire measured once. Scale is a 5-point likert scale. Sub scales include restrained eating, emotional eating, and external eating. Scores will be reported separately for each subscale.
Time Frame
Week 0
Title
Three factor eating inventory
Description
Three factor eating inventory questionnaire measured once. Instrument has three subscales, combining likert scales and true/false questions. Subscales include cognitive restraint (score can range from 0 to 21), disinhibition (score can range from 0 to 16) and hunger (score can range from 0 to 14).
Time Frame
Week 0
Title
Premenstrual Syndrome
Description
Premenstrual Syndrome screening questionnaire measured once. Scale is a 4-point likert. Subscales for premenstrual syndrome (PMS) or premenstrual dysphoric disorder (PMDD), reported separately.
Time Frame
Week 0
Title
General health and well-being
Description
The SF-36 General Health and Well-being questionnaire measured once
Time Frame
Week 0
Title
Usual physical activity
Description
Physical activity estimated from the Stanford Brief Physical Activity questionnaire. Scale is categorical for two subscales: work physical activity and leisure time activity.
Time Frame
Week 0
Title
Change in metabolic rate
Description
Resting and post-prandial metabolic rate measured using indirect calorimetry.
Time Frame
Baseline and 1 hour before lunch meal, 1 hour after lunch meal, and 1 hour after mid-afternoon snack
Title
Change in dietary intake
Description
Dietary intake estimated from 24-hour recall using a web based automated multi-pass method
Time Frame
Ten dietary recalls collected at home during weeks 1-4
Title
Genetic risk of obesity
Description
A polygenic risk score (PRS) indexing genetic predisposition to obesity using known obesity single nucleotide polymorphisms (SNPs).
Time Frame
Week 1
Title
Change in liver fat
Description
Liver fat assessed from the Controlled Attenuation Parameter (CAP) computed from the liver stiffness measurement using the Fibroscan®
Time Frame
Week 0 and 4
Title
Change in liver stiffness
Description
Liver stiffness assessed from the shear wave speed with pulse echo ultrasound using the Fibroscan®
Time Frame
Week 0 and 4

10. Eligibility

Sex
Female
Minimum Age & Unit of Time
18 Years
Maximum Age & Unit of Time
45 Years
Accepts Healthy Volunteers
Accepts Healthy Volunteers
Eligibility Criteria
Inclusion Criteria: Pre-menopausal Body Mass Index 25 - 39.9 kg/m2 Exclusion Criteria: Women who are post-menopausal or peri-menopausal BMI < 25 or > 40 kg/m2 Allergies to tree nuts Using any hormonal contraception including oral contraceptive, contraceptive patch, contraceptive ring, contraceptive injection (e.g. Depo-Provera), or contraceptive implant (e.g. Nexplanon/Implanon) Menstrual cycle lengths < 25 days or > 45 days, or have amenorrhea, eumenorrhea, or polymenorrhea. Pregnant or nursing within the last 6 months, or plan to become pregnant during the trial Medical diagnoses of chronic diseases including cardiovascular or pulmonary diseases, renal disease, cancer, type 1 or type 2 diabetes mellitus, thyroid disease requiring medication, inflammatory bowel disease, irritable bowel disease, or those with recent major surgeries current medical diagnosis of polycystic ovarian syndrome (PCOS).
Facility Information:
Facility Name
USDA, ARS, Western Human Nutrition Research Center
City
Davis
State/Province
California
ZIP/Postal Code
95616
Country
United States

12. IPD Sharing Statement

Plan to Share IPD
No

Learn more about this trial

Snacks and Satiety

We'll reach out to this number within 24 hrs